Tags

Type your tag names separated by a space and hit enter

Effect of tetrahydrocannabinol:cannabidiol oromucosal spray on activities of daily living in multiple sclerosis patients with resistant spasticity: a retrospective, observational study.
Neurodegener Dis Manag. 2018 06; 8(3):151-159.ND

Abstract

AIM

To examine evolution in activities of daily living (ADL) in patients with multiple sclerosis spasticity during long-term use of tetrahydrocannabinol (THC):cannabidiol (CBD) oromucosal spray.

METHODS

Functional impairment was assessed retrospectively (prior to start of treatment) and at the present moment using a 16-item ADL survey; results were compared. A control group without add-on THC:CBD oromucosal spray was included to investigate possible recall bias.

RESULTS

ADL was maintained or slightly improved with THC:CBD oromucosal spray across treatment time (mean 31.9 months) including significant improvement in 'standing up' (p < 0.05) and trends in other items. Significant improvements (p < 0.01) with THC:CBD oromucosal spray were observed in several multiple sclerosis spasticity-related symptoms. Overall, 96.9% of patients using THC:CBD oromucosal spray had a positive global impression of change during treatment.

CONCLUSION

In this pilot study, THC:CBD oromucosal spray maintained or improved aspects of daily functioning. Further study in a larger trial is warranted.

Authors+Show Affiliations

Unidad de Neurología, Hospital General de Elda, Elda (Alicante), Spain.

Pub Type(s)

Journal Article
Observational Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

29851356

Citation

Mallada Frechín, Javier. "Effect of Tetrahydrocannabinol:cannabidiol Oromucosal Spray On Activities of Daily Living in Multiple Sclerosis Patients With Resistant Spasticity: a Retrospective, Observational Study." Neurodegenerative Disease Management, vol. 8, no. 3, 2018, pp. 151-159.
Mallada Frechín J. Effect of tetrahydrocannabinol:cannabidiol oromucosal spray on activities of daily living in multiple sclerosis patients with resistant spasticity: a retrospective, observational study. Neurodegener Dis Manag. 2018;8(3):151-159.
Mallada Frechín, J. (2018). Effect of tetrahydrocannabinol:cannabidiol oromucosal spray on activities of daily living in multiple sclerosis patients with resistant spasticity: a retrospective, observational study. Neurodegenerative Disease Management, 8(3), 151-159. https://doi.org/10.2217/nmt-2017-0055
Mallada Frechín J. Effect of Tetrahydrocannabinol:cannabidiol Oromucosal Spray On Activities of Daily Living in Multiple Sclerosis Patients With Resistant Spasticity: a Retrospective, Observational Study. Neurodegener Dis Manag. 2018;8(3):151-159. PubMed PMID: 29851356.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of tetrahydrocannabinol:cannabidiol oromucosal spray on activities of daily living in multiple sclerosis patients with resistant spasticity: a retrospective, observational study. A1 - Mallada Frechín,Javier, Y1 - 2018/05/31/ PY - 2018/6/1/pubmed PY - 2019/1/3/medline PY - 2018/6/1/entrez KW - THC:CBD oromucosal spray KW - activities of daily living KW - multiple sclerosis KW - spasticity SP - 151 EP - 159 JF - Neurodegenerative disease management JO - Neurodegener Dis Manag VL - 8 IS - 3 N2 - AIM: To examine evolution in activities of daily living (ADL) in patients with multiple sclerosis spasticity during long-term use of tetrahydrocannabinol (THC):cannabidiol (CBD) oromucosal spray. METHODS: Functional impairment was assessed retrospectively (prior to start of treatment) and at the present moment using a 16-item ADL survey; results were compared. A control group without add-on THC:CBD oromucosal spray was included to investigate possible recall bias. RESULTS: ADL was maintained or slightly improved with THC:CBD oromucosal spray across treatment time (mean 31.9 months) including significant improvement in 'standing up' (p < 0.05) and trends in other items. Significant improvements (p < 0.01) with THC:CBD oromucosal spray were observed in several multiple sclerosis spasticity-related symptoms. Overall, 96.9% of patients using THC:CBD oromucosal spray had a positive global impression of change during treatment. CONCLUSION: In this pilot study, THC:CBD oromucosal spray maintained or improved aspects of daily functioning. Further study in a larger trial is warranted. SN - 1758-2032 UR - https://www.unboundmedicine.com/medline/citation/29851356/Effect_of_tetrahydrocannabinol:cannabidiol_oromucosal_spray_on_activities_of_daily_living_in_multiple_sclerosis_patients_with_resistant_spasticity:_a_retrospective_observational_study_ L2 - http://www.futuremedicine.com/doi/full/10.2217/nmt-2017-0055?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -